Phase IIa trial of CX 1739 in patients with central sleep apnoea
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2016
At a glance
- Drugs CX 1739 (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- 11 Jan 2016 The company will present an update about this trial at the Biotech Showcase 2016, according to a RespireRx Pharmaceuticals media release.
- 01 May 2015 This trial will be discussed at the NewYorkBIO 25th Anniversary Conference in May 2015, according to a Cortex Pharmaceuticals media release.
- 08 Apr 2015 New trial record